The October 2017 publication of the Yale School of Medicine recognized an IBS study in the peer-reviewed British Medical Journal. The Yale team conducted a double-blind, randomized clinical trial of patients with Irritable Bowel Syndrome. The experimental group realized statistically significant symptom improvements versus the controls. The study provided data suggesting that the ALCAT test can be used to develop an individualized diet that can alleviate symptoms related to Irritable Bowel Syndrome. In summary, the results showed, "this study provides data suggesting that a leucocyte activation test can be used to develop an individualized diet that can alleviate symptom burden in IBS. These dietary changes may be less restrictive than a low-FODMAP diet, and may result in better long-term adherence."
To review the study in its entirety, please click here: BMJ - Peer reviewed Yale IBS Study
You may also visit the YaleNews site to view the official press release: YaleNews - Alcat Study Press Release
For more information on the benefits of the Alcat test: Cell Science Systems - Alcat Test